The FDA approved axicabtagene ciloleucel (Yescarta) for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy.
The FDA Friday approved axicabtagene ciloleucel (Yescarta) for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy.
The decision was based on data from the phase 2 ZUMA-5 trial (NCT03105336), in which the chimeric antigen receptor (CAR) T-cell treatment elicited a response in 91% of patients with relapsed or refractory follicular lymphoma (n = 81); 74% of patients had a continued remission at 18 months.
Among all patients with follicular lymphoma, the median duration of response was not reached at a median follow-up of 14.5 months.
In the safety analysis conducted in 146 patients, grade 3 or higher cytokine release syndrome and neurologic adverse effects were reported in 8% and 21% of patients, respectively.
In a statement late Friday, Kite, a Gilead company, said the approval marks the first CAR T-cell therapy approved for patients with indolent follicular lymphoma, follows FDA Breakthrough Therapy Designation and a priority review, as well as the third approved indication for a Kite cell therapy.
For these patients in the third line of therapy, the 5-year survival rate is only 20%, said Caron A. Jacobson, MD, MMSc, Medical Director, Immune Effector Cell Therapy Program, Dana-Farber Cancer Institute and Assistant Professor of Medicine, Harvard Medical School.
Enhancing Outpatient Hemophilia Care May Improve Health Outcomes and Costs
May 18th 2024Prospective data from patients attending a rural practice in West Virginia between 2016 and 2023 show that a quality improvement program that followed guideline recommendations and was tailored to specific patient needs reduced preventable bleeds and lowered costs.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen